Project Grant R41CA306625
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Laurel, MD, USA
Similar Awards
- The National Cancer Institute awarded Sinopia Biosciences Inc. $399,873 on September 22, 2025, to develop a metabolomics-enabled artificial intelligence and machine learning platform for discovery of new treatments to enhance drug sensitivity in cancer under the Cancer Biology Research program (CFDA 93.396). Sinopia Biosciences and its partner Omix Technologies are developing algorithms and computational methods to characterize how baseline metabolic states of cancers affect their sensitivity to...
- The National Cancer Institute awarded The Broad Institute, Inc. $694,642 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop live-cell RNA sequencing with single-cell resolution. The project addresses a fundamental limitation in molecular omics measurement: current approaches require cell destruction through lysis, extraction, or fixation to detect molecular contents at high multiplexity, preventing serial measurement of living cells to monitor dynamic processes...
- The National Cancer Institute awarded the Institute For Systems Biology $555,592 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop AI-driven infrastructure for integrating and analyzing cancer datasets and identifying cancer risk factors. The recipient will construct a multi-modal, harmonized resource for the tumor microenvironment featuring an AI-powered spatial search tool. Using spatial datasets from the Human Tumor Atlas Network (HTAN), the...
- The National Cancer Institute awarded The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, $245,297 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop chimeric molecules that trigger generation of neoantigens from proteins dysregulated in infectious disease and cancer. The molecules will be formed by joining clinical-grade protein binders with reactive groups to generate neoantigens that recruit immune system...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded the President and Fellows of Harvard College $604,102 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop bioprinted three-dimensional vascular cancer models that enable study of T cell trafficking, dendritic cell engagement, and tumor cell killing within human and murine tumor microenvironments. The recipient will use microporous embedded printing to fabricate in vitro models incorporating vascular conduits for...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...
- The National Cancer Institute awarded $1,057,841 to Pathware Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) as a Small Business Innovation Research Direct-to-Phase II grant (R44CA302204). Pathware is developing an automated imaging platform combining coded ptychography with artificial intelligence algorithms to evaluate the diagnostic adequacy of unstained lung biopsy samples at the point of care. The system provides rapid on-site evaluation...
- The National Cancer Institute awarded Vivid Bioinnovations, PBC $306,872 on August 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop CAGES (Cell Assemblies in Gel Enclosures), an ultrahigh-throughput platform for screening chimeric antigen receptor T-cell (CAR-T) therapies. The platform encapsulates millions of defined CAR-T and cancer cell interactions in biocompatible gel shells, enabling parallel assay of multi-day co-cultures with direct...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....